Personalis Inc (PSNL)

NASDAQ
Currency in USD
3.560
-0.050(-1.39%)
Closed
After Hours
3.730+0.170(+4.775%)
PSNL Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
3.5213.650
52 wk Range
1.1357.200
Key Statistics
Edit
Prev. Close
3.61
Open
3.54
Day's Range
3.521-3.65
52 wk Range
1.135-7.2
Volume
652.05K
Average Vol. (3m)
1.12M
1-Year Change
143.84%
Book Value / Share
2.86
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PSNL Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
7.333
Upside
+105.99%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period
Show more

Personalis Inc Company Profile

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring, in solid tumor cancers; ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Personalis Inc Earnings Call Summary for Q4/2024

  • Q4 2024 EPS of -$0.23 beats -$0.29 forecast; revenue down 15% YoY to $16.8M
  • Full-year 2024 revenue up 15% to $84.6M; net loss reduced to $81.3M from $108.3M in 2023
  • 2025 revenue projected at $80-90M; targeting reimbursement for two indications
  • Stock falls 5.36% after-hours to $4.15; company focuses on MRD testing market
  • Cash position of $185M; plans to reduce cash usage to $75-80M in 2025
Last Updated: 02/27/2025, 06:20 PM
Read Full Transcript

Compare PSNL to Peers and Sector

Metrics to compare
PSNL
Peers
Sector
Relationship
P/E Ratio
−3.9x−0.4x−0.5x
PEG Ratio
−0.100.110.00
Price / Book
1.5x2.7x2.6x
Price / LTM Sales
3.7x2.3x3.0x
Upside (Analyst Target)
110.7%97.7%54.9%
Fair Value Upside
Unlock6.8%9.8%Unlock

Analyst Ratings

6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.333
(+105.99% Upside)

Earnings

Latest Release
Feb 27, 2025
EPS / Forecast
-0.23 / -0.29
Revenue / Forecast
16.80M / 15.54M
EPS Revisions
Last 90 days

People Also Watch

41.820
INOD
-2.72%
34.75
HIMS
+5.72%
25.710
ASTS
+4.13%
148.50
OLED
-1.90%
2.6400
BFLY
-4.00%

FAQ

What Is the Personalis (PSNL) Stock Price Today?

The Personalis stock price today is 3.56

What Stock Exchange Does Personalis Trade On?

Personalis is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Personalis?

The stock symbol for Personalis is "PSNL."

What Is the Personalis Market Cap?

As of today, Personalis market cap is 314.22M.

What is Personalis Earnings Per Share?

The Personalis EPS is -1.37.

What Is the Next Personalis Earnings Date?

Personalis will release its next earnings report on Apr 30, 2025.

From a Technical Analysis Perspective, Is PSNL a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.